Neuroendocrine Carcinoma Treatment Market Analysis by Gastric Neuroendocrine Tumors and Lung Neuroendocrine Tumors through 2024 to 2034

<p>The global <strong>neuroendocrine carcinoma treatment market </strong>is likely to generate revenue amounting to USD 1,976 million in 2024. Over the assessment period, the industry is projected to expand at an 8.1% CAGR, reaching an industry size of USD 4,305.7 million by the end of 2034.</p><table> <tbody> <tr> <th scope='row'>Attributes</th> <td>Description</td> </tr> <tr> <th scope='row'>Estimated Global Neuroendocrine Carcinoma Treatment Market Size (2024E)</th> <td>USD 1,976 million</td> </tr> <tr> <th scope='row'>Projected Global Neuroendocrine Carcinoma Treatment Market Value (2034F)</th> <td>USD 4,305.7 million</td> </tr> <tr> <th scope='row'>Value-based CAGR (2024 to 2034)</th> <td>8.1%</td> </tr> </tbody></table><p>Country-wise Insights</p><table> <tbody> <tr> <th scope='row'>Countries</th> <td>CAGR 2024 to 2034</td> </tr> <tr> <th scope='row'>India</th> <td>9%</td> </tr> <tr> <th scope='row'>China</th> <td>8.6%</td> </tr> <tr> <th scope='row'>United Kingdom</th> <td>8.4%</td> </tr> <tr> <th scope='row'>France</th> <td>7.5%</td> </tr> <tr> <th scope='row'>United States</th> <td>8.3%</td> </tr> </tbody></table><p>Category-wise Insights</p><table> <tbody> <tr> <th scope='row'>Segment</th> <td>Gastric Neuroendocrine Tumors (Disease Indication Type)</td> </tr> <tr> <th scope='row'>Value Share (2023)</th> <td>46.8%</td> </tr> </tbody></table><table> <tbody> <tr> <th scope='row'>Segment</th> <td>Somatostatin Analogs (Treatment Type)</td> </tr> <tr> <th scope='row'>Value Share (2023)</th> <td>61.2%</td> </tr> </tbody></table>

<p>全球神经内分泌癌治疗市场预计将在2024年实现约19.76亿美元的收益。在评估期内，该行业预计将以8.1%的复合年增长率（CAGR）扩张，并于2034年达到43.057亿美元的产业规模。</p><table> <tbody> <tr> <th scope='row'>属性</th> <td>描述</td> </tr> <tr> <th scope='row'>2024年预计全球神经内分泌癌治疗市场规模</th> <td>19.76亿美元</td> </tr> <tr> <th scope='row'>2034年预计全球神经内分泌癌治疗市场价值</th> <td>43.057亿美元</td> </tr> <tr> <th scope='row'>基于价值的CAGR（2024年至2034年）</th> <td>8.1%</td> </tr> </tbody></table><p>按国家划分的洞察</p><table> <tbody> <tr> <th scope='row'>国家</th> <td>2024年至2034年CAGR</td> </tr> <tr> <th scope='row'>印度</th> <td>9%</td> </tr> <tr> <th scope='row'>中国</th> <td>8.6%</td> </tr> <tr> <th scope='row'>英国</th> <td>8.4%</td> </tr> <tr> <th scope='row'>法国</th> <td>7.5%</td> </tr> <tr> <th scope='row'>美国</th> <td>8.3%</td> </tr> </tbody></table><p>按类别划分的洞察</p><table> <tbody> <tr> <th scope='row'>细分市场</th> <td>胃神经内分泌肿瘤（疾病指示类型）</td> </tr> <tr> <th scope='row'>价值份额（2023年）</th> <td>46.8%</td> </tr> </tbody></table><table> <tbody> <tr> <th scope='row'>细分市场</th> <td>生长激素释放激素类似物（治疗类型）</td> </tr> <tr> <th scope='row'>价值份额（2023年）</th> <td>61.2%</td> </tr> </tbody></table>